Fayez Sarofim & Co’s PLx Pharma Inc. Common Stock PLXP Stock Holding History

Fayez Sarofim & Co’s Portfolio PLXP Stock Details PLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,729	Closed	-$1.79K	–	291
2023 Q1	$1.79K	Hold	13,729	–	–	﹤0.01%	281
2022 Q4	$2.25K	Hold	13,729	–	–	﹤0.01%	281
2022 Q3	$9K	Hold	13,729	–	–	﹤0.01%	278
2022 Q2	$33K	Hold	13,729	–	–	﹤0.01%	289
2022 Q1	$55K	Hold	13,729	–	–	﹤0.01%	320
2021 Q4	$110K	Hold	13,729	–	–	﹤0.01%	336
2021 Q3	$265K	Hold	13,729	–	–	﹤0.01%	288
2021 Q2	$189K	Hold	13,729	–	–	﹤0.01%	313
2021 Q1	$124K	Hold	13,729	–	–	﹤0.01%	287
2020 Q4	$76K	Hold	13,729	–	–	﹤0.01%	270
2020 Q3	$44K	Hold	13,729	–	–	﹤0.01%	265
2020 Q2	$44K	Hold	13,729	–	–	﹤0.01%	258
2020 Q1	$31K	Hold	13,729	–	–	﹤0.01%	238
2019 Q4	$60K	Hold	13,729	–	–	﹤0.01%	269
2019 Q3	$70K	Hold	13,729	–	–	﹤0.01%	251
2019 Q2	$99K	Hold	13,729	–	–	﹤0.01%	250
2019 Q1	$72K	Hold	13,729	–	–	﹤0.01%	246
2018 Q4	$21K	Hold	13,729	–	–	﹤0.01%	237
2018 Q3	$56K	Hold	13,729	–	–	﹤0.01%	240
2018 Q2	$54K	Hold	13,729	–	–	﹤0.01%	244
2018 Q1	$46K	Hold	13,729	–	–	﹤0.01%	247
2017 Q4	$95K	Hold	13,729	–	–	﹤0.01%	245
2017 Q3	$89K	Buy	+13,729	New	+$88.1K	﹤0.01%	240

Other funds holding PLXP

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.28B AUM 38.1% 1-Year Est. Return

Fayez Sarofim & Co's PLXP Position: Q2 2023 in Review

Fayez Sarofim & Co sold out of PLx Pharma Inc. Common Stock (PLXP) in Q2 2023, closing a stake of 13,729 shares — an estimated $1.79K sold.

Fayez Sarofim & Co first reported a position in PLXP in Q3 2017 and held it in 23 quarters. The position peaked at $265K in Q3 2021. 4 funds tracked by Wall St. Rank hold PLXP as of Q2 2023.

Fayez Sarofim & Co reported no remaining PLx Pharma Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Fayez Sarofim & Co sold 13,729 PLx Pharma Inc. Common Stock shares in Q2 2023, an estimated $1.79K.
Fayez Sarofim & Co first reported a position in PLx Pharma Inc. Common Stock in Q3 2017 and held it in 23 quarters.
Fayez Sarofim & Co's PLx Pharma Inc. Common Stock position peaked at $265K in Q3 2021.
4 funds tracked by Wall St. Rank held PLx Pharma Inc. Common Stock as of Q2 2023.

Based on Fayez Sarofim & Co's 13F filing for Q2 2023, filed 14 Aug 2023.